BridgeBio to Unveil New Acoramidis Data at ESC-Heart Failure 2026

Event summary

  • BridgeBio will present new data from the Phase 3 ATTRibute-CM study at ESC-Heart Failure 2026 in Barcelona, Spain, May 9-12, 2026.
  • Bayer, BridgeBio’s European licensing partner, will deliver a late-breaking oral presentation on acoramidis’ impact on outpatient worsening heart failure.
  • Acoramidis is approved as Attruby® in the U.S. and BEYONTTRA® in Europe, Japan, Switzerland, and the UK for treating transthyretin amyloid cardiomyopathy (ATTR-CM).
  • Key presentations include data on disease progression, biomarkers, and clinical outcomes, with a focus on NT-proBNP levels and KCCQ-OS scores.

The big picture

BridgeBio’s presentation of new acoramidis data at ESC-Heart Failure 2026 underscores the company’s focus on genetic conditions, particularly in the underserved ATTR-CM market. The strategic partnership with Bayer for European distribution highlights BridgeBio’s decentralized model, designed for speed and scalability. The data could further solidify acoramidis’ position as a leading treatment option, potentially expanding its reach in global markets.

What we're watching

Clinical Efficacy
How the new data on acoramidis’ impact on NT-proBNP levels and KCCQ-OS scores will influence its market positioning against competitors.
Regulatory Dynamics
Whether the positive outcomes presented will accelerate regulatory approvals or label expansions in key markets.
Commercial Strategy
The pace at which BridgeBio and Bayer can leverage these data to drive adoption and market share in the ATTR-CM space.